RNA silencing of glycolysis pathway in Toxoplasma gondii

Journal of Eukaryotic Microbiology

Volumn 53, Issue SUPPL. 1, 2006, Pages

  Ananvoranich, Sirinart ^a   Al Rayes, Marwan ^a   Al Riyahi, Ahmad ^a   Wang, Xiang ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE; TRITIUM;

GENE; GENETICS; PROTOZOAN; RNA;

ANIMAL; CELL LINE; CELL PROLIFERATION; CONFERENCE PAPER; FIBROBLAST; GENETICS; GLYCOLYSIS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PARASITOLOGY; RNA INTERFERENCE; TOXOPLASMA;

ANIMALS; CELL LINE; CELL PROLIFERATION; FIBROBLASTS; GLYCOLYSIS; HYPOXANTHINE; RNA INTERFERENCE; TOXOPLASMA; TRITIUM;

TOXOPLASMA GONDII;

EID: 33751372932     PISSN: 10665234     EISSN: 15507408     Source Type: Journal    
DOI: 10.1111/j.1550-7408.2006.00216.x     Document Type: Conference Paper

References (13)

1. Al-Anouti, F., Quach, T. & Ananvoranich, S. 2003. Double-stranded RNA can mediate the suppression of uracil phosphoribosyltransferase expression in Toxoplasma gondii. Biochem. Biophys. Res. Commun., 302:316-323.
2. Black, M. W. & Boothroyd, J. C. 2000. Lytic cycle of Toxoplasma gondii. Microbiol. Mol. Biol. Rev., 64:607-623.
3. Boothroyd, J. C., Black, M., Bonnefoy, S., Hehl, A., Knoll, L. J., Manger, I. D., Ortega-Barria, E. & Tomavo, S. 1997. Genetic and biochemical analysis of development in Toxoplasma gondii. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 352:1347-1354.
4. Brady, R. L. & Cameron, A. 2004. Structure-based approaches to the development of novel anti-malarials. Curr. Drug Targets, 5:137-149.
5. Idro, R., Jenkins, N. E. & Newton, C. R. 2005. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol., 4:827-840.
6. Kissinger, J. C., Gajria, B., Li, L., Paulsen, I. T. & Roos, D. S. 2003. ToxoDB: accessing the Toxoplasma gondii genome. Nucleic Acids Res., 31:234-236.
7. Lakhdar-Ghazal, F., Blonski, C., Willson, M., Michels, P. & Perie, J. 2002. Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Curr. Top. Med. Chem., 2:439-456.
8. Louassini, M., Foulquie, M., Benitez, R. & Adroher, J. 1999. Citric-acid cycle key enzyme activities during in vitro growth and metacyclogenesis of Leishmania infantum promastigotes. J. Parasitol., 85:595-602.
9. Roos, D. S. 2005. Genetics. Themes and variations in apicomplexan parasite biology. Science, 309:72-73.
10. Roos, D. S., Donald, R. G., Morrissette, N. S. & Moulton, A. L. 1994. Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Meth. Cell Biol., 45:27-63.
11. Taylor, M. A. & Webster, K. A. 1998. Recent advances in the diagnosis in livestock of Cryptosporidium, Toxoplasma, Giardia and other protozoa of veterinary importance. Res. Vet. Sci., 65:183-193.
12. Tomavo, S. 2001. The differential expression of multiple isoenzyme forms during stage conversion of Toxoplasma gondii: an adaptive developmental strategy. Int. J. Parasitol., 31:1023-1031.
13. Verlinde, C. L., Hannaert, V., Blonski, C., Willson, M., Perie, J. J., Fothergill-Gilmore, L. A., Opperdoes, F. R., Gelb, M. H., Hol, W. G. & Michels, P. A. 2001. Glycolysis as a target for the design of new antitrypanosome drugs. Drug Resist. Update, 4:50-65.